Author Archives: admin


When aid-in-dying means you have to go before youre ready – Monterey Herald

When Sandy Morris found out she would die of ALS, she resolved that she would bravely, peacefully and legally end her own life, surrounded by her beloved family and views of the Sierra Nevada.

The challenge is: How?

Californias End of Life Option Act requires that people take their own lethal medications, without assistance but the cruel reality for Sandy and others dying of neuromuscular disease is that they cant. They need help.

On Friday, the iron-willed 55-year-old wife, mother and former athlete, joined by other patients and physicians, filed suit in federal court asserting discrimination under the states historic law. Because they are disabled, they say, theyre denied access to the dignified death available to all other Californians.

It is so incredibly cruel that nobody can help me take these medications, said Morris, confined to her bed in Sierraville, north of Lake Tahoe. I am terrified to think that if I wait too long if I wake up tomorrow or the next day and cant move my thumbs or swallow that suddenly this is no longer an option for me.

If the courts allow her doctor to help administer the drugs she needs for a peaceful goodbye, I can stay with my children a few extra weeks, or days, or hours, she said, her voice breaking.

But Ill have to leave this beautiful world earlier thanI want to, she said, while I still have the use of my hands and while I can still swallow.

Under the End of Life Option Act, used by 1,816 Californians since it went into effect in 2016, it is legal for doctors and family members to prepare medications, put them in a drink or pour them into a syringe or pump attached to a feeding tube.

But the patient needs to suck the straw on their own. They cant help the patient push a plunger on the syringe. If the medications get stuck while flowing from a bag into a feeding tube, risking a dangerous partial dose, they cant fix it by squeezing the bag.

Thats considered assisting a suicide a felony, punishable by up to three years in prison and/or a $10,000 fine. Doctors could lose their licenses.

More than two-thirds of patients who use the Act are dying of cancer.

But the second-largest category of underlying illness accounting for 10% of all cases are people with common neurological diseases and movement disorders such as amyotrophic lateral sclerosis (ALS), Parkinsons, multiple sclerosis, stroke or paralysis from spinal injury.

Theyre faced with a terrible decision: die early or suffer.

They come to this place where they feel pressured to act, said attorney Kathryn Tucker of Emerge Law Group, who is filing the civil rights class-action suit.

For Sandy, choosing to wait might mean suffocating to death. ALS is a progressive neurodegenerative illness that affects nerve cells in the brain and the spinal cord, eventually paralyzing your chest muscles. Often called Lou Gehrigs disease, after the death of the famed Yankee first baseman, it also claimed the lives of playwright Sam Shepard, jazz musician Charles Mingus and San Francisco 49ers receiver Dwight Clark.

Her mind is still razor sharp. She can still feel every sensation. With difficulty, she is still able to speak. But nothing else moves. My brain will say kick, and my feet are ready. Theyre still beautiful, she said. But the neurons have died. They are no longer able to send the message.

Doctors who help the terminally ill confront a legal dilemma: Disability law mandates assistance and equal access to health care, while the aid-in-dying law mandates the opposite.

I am trapped between two contradictory laws, said Dr. Lonny Shavelson of Berkeley, chair of the American Clinicians Academy on Medical Aid in Dying. When working with a patient with neuromuscular disease or various other neurological diseases, Im forced to break one law or the other. Theres no other choice.

Californias law, modeled after Oregons statute, was written by politicians and advocates, not doctors and ethicists, said Dr. Robert Brody of San Francisco General Hospital and Professor of Medicineand Family and Community Medicine at UC San Francisco.

To appease opponents of the act, the language was very restrictive, he said. Rules not only preclude help but also require patients to be of clear mind and capable of making three requests, orally and in writing, separated by a minimum of 15 days. Two witnesses are required for a patients signature on the written request. Patients must sign a final attestation form no more than 48 hours before ingesting the drug.

Now its time to improve the law, Brody said, with the political courageto take on the vested interests who didnt want this law in the first place, who dont want the law now and who have demanded these so-called safeguards, he said.

These safeguards have turned out to be barriers, he said.

According to bioethicist Alicia Ouellette, dean of New Yorks Albany Law School and an expert in health law and disability rights, the law prevents competent, terminally ill people with neurologic diseases from accessing aid in dying because they cannot physically administer the medications. The unassisted self-administration requirement creates a barrier to health services available to people without those disabilities. This barrier runs contrary to disability rights laws.

Opponents say safeguards are essential to prevent an heir or abusive caregiver from coercing the patient to take the deadly drugs. People with disabilities may feel theyre a burden on loved ones, and abuse is a growing but often undetected problem, according to the group Not Dead Yet, a New York-based disability rights group that calls aid-in-dying laws a deadly form of discrimination.

Clinicians are allowed to administer medicine in almost every other jurisdiction in the world that allows aid in dying, such as Canada, Australia, New Zealand, Colombia, Spain, Netherlands, Belgium and Luxembourg. Switzerland and the U.S. require self-administration.

The law should not discriminate against people with disabilities by forcing them to consider this most personal decision before they are ready, said Fred Fisher, CEO of the ALS Association Golden West Chapter. The group neither supports nor opposes the law, saying it is a matter of individual conscience.

Sandy Morris was once an energetic woman who skied, hiked, ran the Lake Tahoe Marathon and worked for years as global analytics business manager for Hewlett-Packard. Married to her best friend, she was fiercely committed to family life, organizing fancy birthday parties, planning college tours and waking before dawn to help braid the mane of her daughters paint horse, Sunny, for show competition.

We had a fairytale upbringing. I woke up every morning knowing that I was completely safe and held, said her daughter, Kylan, 24. I want every minute that shes still here on Earth with us.

Sandy was only 51 when she was diagnosed, after noticing that her right foot slapped the sidewalk when she walked. Desperate for a cure, she joined a clinical trial at California Pacific Medical Center, endured three spinal infusions and four lumbar punctures, and flew to South Korea for a stem-cell experiment.

As the disease progresses, its like an anaconda snake that swallows you whole, then squeezes you to death, she said. And theres no way out.

For four years, I fought this disease to the best of my ability, she said. While she knew it was fatal, she took solace that the End of Life Options Act meant that my children and my husband would not have to watch me gasp for my last breath.

Shes frustrated that help is available for every possible need from eating and bathing to scratching an itch yet not for dying.

It feels so unfair that because I am disabled, Im going to have to pick a day, and leave this world earlier than I want to, she said.

Ill miss the weddings and the grandchildren, she said. At least let me stay for the very last second, until my bravery is over, with my babies and my husband and my beautiful life.

Visit link:
When aid-in-dying means you have to go before youre ready - Monterey Herald

New fault lines emerge in Car-T therapy – Vantage

For Car-T therapy to become anything other than a niche hospital procedure it has to move into early treatment lines. Novartiss Kymriah seems unlikely to secure such an accolade, however, having today failed to beat autologous stem cell transplantation in a second-line lymphoma study.

For the Swiss group this is especially galling as Kymriahs two big competitors, Bristol Myers Squibbs Breyanzi and Gileads Yescarta, have just succeeded in similar trials. Still, it will be important to bear in mind trial design differences, though one take is that important fault lines are emerging between CD19-directed Car-T therapies.

On a cross-study basis this was already becoming apparent in these treatments approved salvage uses in second-line or later lymphoma, where for instance Yescarta and Breyanzi boast overall remission rates above 70% while Kymriahs is 50%, according to US prescribing information.

Second line

Now the battle lines move to second-line lymphoma, an important setting where patients have relapsed after or are refractory to front-line Rituxan plus chemo.

Belinda, the trial Novartis today said had failed, compared giving these patients Kymriah head to head against the standard of care of chemo followed, in responders, by autologous transplant. Novartis said Belindas primary endpoint, event-free survival (EFS), failed to show a benefit for Kymriah.

An important point is that Belinda allowed the option of platinum-based immunochemotherapy before dosing Kymriah or the standard of care, a fact that might have rendered any subsequent benefit statistically insignificant.

Bristols corresponding Transform and Gileads Zuma-7 studies had similar designs and also tested EFS as primary endpoint, though they did not have the immunochemotherapy option. On June 10 Bristol said Breyanzi had beaten chemo plus transplant in terms of EFS, as well as in terms of complete response rates.

Two weeks later Yescarta scored in Zuma-7, with Gilead quantifying the EFS benefit versus chemo and transplant as a 60% reduction in event risk (p<0.0001). There was also a benefit in overall remission rate; overall survival was insufficiently maturefor Transform and Zuma-7 alike.

Note: *all 2nd line after Rituxan + chemo, compared against standard of care/autologous transplant in responders; **included the option of platinum immunochemotherapy before Kymriah or SoC. BCL=B-cell lymphoma; DLBCL=diffuse large B-cell lymphoma. Source: company statements.

Next it will be time to pick apart the data, with a clear focus falling on the possible effect of Belinda's addition of platinum immunochemotherapy.

In terms of disease criteria, Zuma-7 enrolled only diffuse large B-cell lymphoma patients, while Transform and Belinda both specified aggressive B-cell lymphoma but allowed subjects with grade 3B follicular lymphoma, a less aggressive type.

The precise balance of baseline characteristics will be scrutinised to see whether the studies offer an apples-to-apples comparison. A similar thing goes for subsequent therapy. How many patients in each studys control cohorts went on to receive Car-T, and did this influence outcomes? How durable are responses and what will the gold standard of median overall survival tell us once it is reached?

Some answers should be forthcoming when full data from these recent interim analyses are presented, perhaps at Decembers Ash meeting. In the meantime doctors and analysts alike will digest the emerging data suggesting that Kymriah, the first Car-T therapy to make it to market, might not be the best.

See the rest here:
New fault lines emerge in Car-T therapy - Vantage

Dr. Death Season 1 Review: Truth continues to be stranger than fiction. – Times of India

Dr. Death Story: Based on the real-life story of a neurosurgeon in Texas, USA who maimed several patients and killed two of them.

Review: The pilot episode begins with voices of patients who have suffered at the hands of Dr Christopher Duntsch (Joshua Jackson) as the camera slowly zooms in to his face. Then, we meet one of his patients Madeline Beyer (Maryann Plunkett), prepping for a routine surgery under his care. Shes optimistic in the hands of one of the most reputable surgeons in Dallas, Texas. But when she emerges, shes worse than before. Far worse, in fact, as we find out when Dr Robert Henderson (Alec Baldwin) assesses her case and condition. Baffled by the results of her surgery, he reaches out to Dr Randall Kirby (Christian Slater), a hotshot motormouth surgeon who previously worked with Dr Duntsch. But, as the two surgeons investigate Duntschs case history and unearth his medical background, they discover many deadly mess-ups, damning cover-ups and downright lies.

To say this series is spine-chilling (if you excuse the pun) would be an understatement. The horrors that unfold in front of trained professionals, who are either unable to act or turn a blind eye because of protocol or financial reasons, goes beyond medical malpractice. We slowly learn about the shocking practices at the hands of a surgeon, who, at first glance, appears to be on the top of his game. Dr Christopher Duntsch (Joshua Jackson) is a charismatic and self-assured young doctor who strings everyone along with his conviction. He believes hes the future of non-invasive surgery and will change the course of medical history with his cutting-edge stem-cell research. But Christopher Duntsch is inherently unsettling from the get-go. Hes dismissive of anyone who challenges his integrity and repeatedly proclaims his excellence, rattling off his credentials to placate concerned patients or their family members. As a young college student, he constantly messes up his routines during football practice and seems to struggle with basic directions. Thats not to say he isnt determined. Every time hes down, he finds a way to get back on the horse. But theres a world of difference between dropping the ball on the field and messing up in surgery.

Trying to understand the extent of his devastation is daunting. Doctors Robert Henderson (Alec Baldwin) & Randall Kirby (Christian Slater) take it on themselves to look into how he got away with murder, literally, while trying to prevent him from ruining any more lives. The narrative goes from allowing events to unravel from their perspective while giving us a peek into his psyche. The show keeps us wondering if the neurosurgeon is entirely delusional or intentionally harmful. This is supplemented by Joshua Jacksons chilling depiction of Christopher Duntsch. The actor deftly manages the extremes of Duntschs fluctuating persona between vulnerability and arrogance. Through his portrayal, the show does not prosecute Christopher Duntsch by presenting him as an evil deviant. Instead, it opts to paint him as accurately as possible, cinematic licenses notwithstanding. Its no easy task, but despite everyone around eventually abandoning the man dubbed Dr Death by the media, Joshua Jackson manages to humanize him.

On the other hand, Alec Baldwin & Christian Slater are captivating to watch as doctors Robert Henderson & Randall Kirby, respectively. Baldwins calm and calculated demeanour offsets Slaters frenetic energy forming the perfect odd-couple dynamic to lead us through the mini-series. As Henderson and Kirby try to unearth the extent of Duntschs butchery, they also discover how he could get away with it for so long. Later in the series, AnnaSophia Robb enters as Michelle Shughart, the spirited prosecutor who gradually builds a case against the doctor. Robb lends a more passionate angle to bringing justice for the affected victims.

The show utilizes secondary characters to flesh out the emotional beats. Fredric Lehne as Don Duntsch Christophers father, Grace Gummer as Kim Morgan a nurse who became his assistant, and Dominic Burgess as Jerry Summers - Christophers confidante and, probably, his biggest blunder, are all instrumental in giving more context to the disgraced doctors mindset. Although the series never fully addresses the reasons behind what he did, the results are excruciating enough.

Show creator Patrick Macmanus with directors Maggie Kiley, Jennifer Morrison, and So Yong Kim choose to jump around timelines to bring different angles to the carnage. While this method presents a well-rounded interpretation of events, it becomes slightly perplexing to grasp over the last couple of episodes. Its the only detriment to an otherwise captivating series far more sinister than most horror fare. After all, the truth continues to be stranger than fiction.

Read the original here:
Dr. Death Season 1 Review: Truth continues to be stranger than fiction. - Times of India

Circulating Tumor Cells (CTC) Diagnostics Market is expected to Account for Over US$ 9.5 Million in – PharmiWeb.com

Circulating tumor cells (CTCs) are a blistering topic of oncological conferences and research due to their tremendous potential in the area of cancer diagnosis as well as treatment. The amount of research that CTCs have been doled with signals the lucrative growth prospects of theCTC diagnostics market, which is likely to surpass the valuation of over US$ 9.5 billion by 2030 projects a recent study published by Fact.MR.

The study highlights the potential for the CTC enrichment technologies in the area of CTC diagnostics and remains bullish on the profitability of investments made in this space. The potentiality of CTC diagnostics is not limited to diagnosing the presence of a tumor, but it also goes beyond that to help in finding the core information about that tumor. In the coming years, the significance of CTC diagnostics in cancer therapies and treatment is expected to remain substantial and the market will witness astonishing growth in the coming decade, opines the Fact.MR study.

Request a report sample to gain comprehensive insights at https://www.factmr.com/connectus/sample?flag=S&rep_id=5510

The CTC diagnostics technology possesses the ability to detect, identify, quantify, and analyze cancer tumors in blood samples of patients. It is gaining immense demand in the area of cancer diagnostics as patients inclination toward non-invasive tests is significantly high. Players in the CTC diagnostics market must tap into opportunities in the area of targeted cancer research and diagnosis to benefit from the great potential that CTC diagnostics carry in the cancer diagnostics landscape in the coming years, says a lead analyst at Fact.MR.

Request More Information about Report Methodology https://www.factmr.com/connectus/sample?flag=RM&rep_id=5510

The incidence of cancer is alarming across the world, and researchers are constantly on their toes to improve the diagnostics and cancer treatments to reduce the avoidable cancer deaths. CTC diagnostics is emerging as an important area of cancer stem cell research as the reliability of using CTC counts from blood samples of patients can help doctors and oncologists to make an appropriate choice of frontline cancer therapy. A mounting number of researchers are implementing CTC diagnostic technologies in cancer stem cell research as it provides doctors with a decision algorithm so as to opine on which treatment to choose.

Fact.MR has published a study on the CTC diagnostics market which offers a detailed assessment on how the CTC diagnostics market will grow and expand in the coming decade. The report analyzes the statistics related to the market growth during the historic period of 2015-2019, and with the help of which, it offers the detailed assessment on growth projections for the landscape during the forecast period of 2020-2030.

Fact.MRs report categorises the insights on the CTC diagnostics market in the form of product (Devices & Systems, Kits & Reagents, Other Consumables), technology (CTC Enrichment Methods, CTC Detection Methods, and CTC Analysis), application (Cancer Stem Cell Research, EMT Biomarkers Development, Tumorigenesis Research, and Others), sample type (Blood, Bone Marrow, and Others), and seven key regions (North America, Latin America, East Asia, South Asia, Oceania, Middle East & Africa, and Europe).

Explore Fact.MRs Coverage on the Healthcare Domain

Microcirculation Microscope Market: A recent study by Fact.MR on the Microcirculation Microscope market offers an unbiased analysis on the opportunities and trends through 2021 and beyond. The study analyzes crucial trends that are currently determining market growth. This report explicates on vital dynamics, such as the challenges, restraints, and opportunities for key market players along with key stakeholders and emerging players.

Scanning Probe Microscopes Market: A detailed assessment of Scanning Probe Microscopes market value chain analysis, business execution, and supply chain analysis across regional markets has been covered in the report. A list of prominent companies operating in the market along with their product portfolios enhances the reliability of this comprehensive research study.

Microscopy Devices Market: Fact.MR delivers a detailed analysis on global Microscopy Devices market with the strategies and competitive landscape for the upcoming period. The key players market share data provided by the report given you a detailed insights on the shortcomings and forthcomings of the market for the forecast period.

About Fact.MR

Market research and consulting agency with a difference! Thats why 80% of Fortune 1,000 companies trust us for making their most critical decisions. We have offices in US and Dublin, whereas our global headquarter is in Dubai. While our experienced consultants employ the latest technologies to extract hard-to-find insights, we believe our USP is the trust clients have on our expertise. Spanning a wide range from automotive & industry 4.0 to healthcare & retail, our coverage is expansive, but we ensure even the most niche categories are analyzed.Reach out to uswith your goals, and well be an able research partner.

Contact: US Sales Office: 11140 Rockville Pike Suite 400 Rockville, MD 20852 United States Tel:+1 (628) 251-1583 E:sales@factmr.com Research Insight:https://www.factmr.com/report/circulating-tumor-cells-ctc-diagnostics-market Press Release:https://www.factmr.com/media-release/1818/global-circulating-tumor-cells-ctc-diagnostics-market Follow Us:LinkedIn|Twitter

More here:
Circulating Tumor Cells (CTC) Diagnostics Market is expected to Account for Over US$ 9.5 Million in - PharmiWeb.com

COVID-19 in children with cancer: Severe disease and disrupted treatment – Markets Insider

MEMPHIS, Tenn., Aug. 26, 2021 /PRNewswire/ --Research from a large international effort shows that 20% of children with cancer who are infected with SARS-CoV-2 develop severe infections. In studies of children overall, only 1-6% have reported severe infections. The results come from the Global Registry of COVID-19 in Childhood Cancer, which was launched by St. Jude Children's Research Hospital and the International Society of Paediatric Oncology (SIOP). The registry gathers data on the pandemic's effect on this unique patient population. The findings were published today in The Lancet Oncology.

Scientists from St. Jude and SIOP report results from the Global Registry of COVID-19 and Childhood Cancer.

Results from the registry indicated that in addition to more severe or critical infections, pediatric cancer patients were more likely to be hospitalized and die than were other children. The pandemic also disrupted cancer treatment. These effects were observed more significantly in low- and middle-income countries, where the odds of severe or critical disease from COVID-19 were nearly 6 times higher than in high-income countries.

"The results clearly and definitively show that children with cancer fare worse with COVID-19 than children without cancer," said corresponding author Sheena Mukkada, M.D., St. Jude Departments of Global Pediatric Medicine and Infectious Diseases. "This global collaboration helps clinicians make evidence-based decisions about prevention and treatment, which, unfortunately, remain relevant as the pandemic continues."

A greater burden for childhood cancer patients

This is the first multinational study to describe the outcomes of a large cohort of children and adolescents with cancer or hematopoietic stem cell transplantation and laboratory diagnosis of COVID-19. The registry remains open and is enrolling children younger than 19 years old.

The analysis looked at 1,500 children from 131 hospitals in 45 countries from April 15, 2020, to February 1, 2021. This is prior to vaccinations becoming available to older children in some areas of the globe, as well as prior to the emergence of certain disease variants, including delta, which are responsible for the new surge and have become a major global concern.

The study found that 65% of patients were hospitalized and 17% required admission or transfer to a higher level of care. It also showed that 4% of patients died due to COVID-19 infections, compared to 0.01-0.7% mortality reported among general pediatric patients. Cancer care was also affected. Cancer therapy was modified in 56% of patients and 45% had chemotherapy withheld while their infections were treated.

"By working together to create this global registry, we have enabled hospitals around the world to rapidly share and learn how COVID-19 is affecting children with cancer," said the paper's co-author, Professor Kathy Pritchard-Jones, SIOP president. "The results are reassuring that many children can continue their cancer treatment safely, but they also highlight important clinical features that may predict a more severe clinical course and the need for greater vigilance for some patients."

A global pandemic and a global response

The registry suggests biologic factors that likely influence how children with cancer respond to COVID-19. Those include immune system function and the underlying disease. Analysis also showed that outcomes vary around the world, although the registry does not pinpoint causes. This variation may be due to a multitude of factors, including disruptions from the pandemic, access to care and resources, or delays in infection diagnosis.

Results from the registry are a call to action to address inequities in access to protective and effective treatment measures against the COVID-19 pandemic worldwide.

"Understanding a global crisis like COVID-19 requires our entire childhood cancer community around the world to come together to respond," said senior author Carlos Rodriguez-Galindo, M.D., St. Jude Global director. "The impact of this disease has been felt in every corner of the world, but particularly in low- and middle-income countries compared to high-income countries. There are critical differences based on where a child lives.This registry is a tool that is helping us understand what that means for children with cancer everywhere."

The registry is still enrolling patients and continues to add new countries. It includes freely available data-visualization tools so that anyone, anywhere, can access the information.

Learn more about COVID-19 and vaccination

Vaccinations against COVID-19 have been demonstrated to be safe and effective in preventing severe forms of the disease, helping patients avoid hospitalizations and the need for mechanical ventilation. In the United States, vaccines are available and encouraged for children 12 years of age and older. Vaccination is one way to protect not only yourself but your community, including those who are at high risk of severe disease such as children with cancer.

Learn more about how Vaccines Bring Us Closer and check out COVID-19 resources from St. Jude.

Authors and Funding

The study's other authors are Guillermo Chantada, Hospital San Joan de Deu Barcelona, Spain; Rashmi Dalvi, Bombay Hospital Institute of Medical Sciences Mumbai, India; Laila Hessissen, Mohammed V University Rabat, Morocco; Michael Sullivan, University of Melbourne, Australia; Eric Bouffet, Hospital for Sick Children Toronto, Canada; Nickhill Bhakta, Yichen Chen, Yuvanesh Vedaraju, Lane Faughnan, Maysam Homsi, Hilmarie Muniz-Talavera, Radhikesh Ranadive, Monika Metzger, Paola Friedrich, Asya Agulnik, Sima Jeha, Catherina Lam, Daniel Moreira, Victor Santana, Miguela Caniza and Meenakshi Devidas of St. Jude; and more than 150 members of the Global Registry of COVID-19 in Childhood Cancer.

The study was funded by the National Institutes of Health (Cancer Center Support grant CA21765), and ALSAC, the fundraising and awareness organization of St. Jude.

About SIOP

Established in 1969, the International Society of Paediatric Oncology (SIOP), is the only global multidisciplinary society entirely devoted to paediatric and adolescent cancer. The society has over 1,800 members worldwide including physicians, nurses, other health-care professionals, scientists and researchers. Our members are dedicated to increasing knowledge about all aspects of childhood cancer. SIOP envisions that "no child should die of cancer" and is aiming to improve the lives of children and adolescents with cancer through global collaboration, education, training, research and advocacy. To learn more, visit siop-online.org or follow SIOP on social media at @WorldSIOP.

About St. Jude Global

St. Jude Children's Research Hospital established the Department of Global Pediatric Medicine in 2016 as a new academic department to address the global challenges in pediatric cancer and catastrophic diseases, and to build on its previous work to reduce disparities in access to care. As a result, St. Jude Global launched in 2018 to support the advancement of care for children with cancer and other catastrophic diseases through the development of comprehensive initiatives in capacity building, education and research. St. Jude Global is committed to ensuring that every child will have access to quality care and treatment no matter where in the world they live.

St. Jude Children's Research Hospital

St. Jude Children's Research Hospital is leading the way the world understands, treats and cures childhood cancer and other life-threatening diseases. It is the only National Cancer Institute-designated Comprehensive Cancer Center devoted solely to children. Treatments developed at St. Jude have helped push the overall childhood cancer survival rate from 20% to 80% since the hospital opened more than 50 years ago. St. Jude freely shares the breakthroughs it makes, and every child saved at St. Jude means doctors and scientists worldwide can use that knowledge to save thousands more children. Families never receive a bill from St. Jude for treatment, travel, housing and food because all a family should worry about is helping their child live. To learn more, visit stjude.org or follow St. Jude on social media at @stjuderesearch.

View original content to download multimedia:https://www.prnewswire.com/news-releases/covid-19-in-children-with-cancer-severe-disease-and-disrupted-treatment-301361700.html

SOURCE St. Jude Children's Research Hospital

Here is the original post:
COVID-19 in children with cancer: Severe disease and disrupted treatment - Markets Insider

BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma – Business Wire

CAMBRIDGE, Mass. & BEIJING & HEMEL HEMPSTEAD, England--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ:BGNE; HKEX:06160) and EUSA Pharma (UK), Ltd. today announced that the China National Medical Products Administration (NMPA) has granted QARZIBA (dinutuximab beta) conditional approval for the treatment of high-risk neuroblastoma in patients aged 12 months and above who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed or refractory (R/R) neuroblastoma with or without residual disease. Dinutuximab beta is a targeted immunotherapy approved by the European Medicines Agency (EMA).i

Dinutuximab beta represents an important biologic therapy for pediatric patients in China, having been listed in the first batch of New Drugs in Urgent Clinical Need Marketed Overseas by the NMPA, commented Xiaobin Wu, Ph.D., President, Chief Operating Officer, and General Manager of China at BeiGene. For these young patients fighting neuroblastoma in China, we are proud to bring the first approved treatment.

We are delighted that the benefit of dinutuximab beta has been recognized in China. This approval represents an important milestone in our mission and collaboration with BeiGene of bringing innovative cancer and rare disease therapies to patients, said Carsten Thiel, Ph.D., Chief Executive Officer of EUSA Pharma.

The approval of dinutuximab beta in China for the treatment of patients with high-risk neuroblastoma was supported by clinical results available from key trials conducted by SIOPEN (The International Society of Paediatric Oncology Europe Neuroblastoma Group) in collaboration with APEIRON Biologics and EUSA Pharma. These randomized controlled trials evaluated the efficacy of dinutuximab beta by comparing the administration of dinutuximab beta with and without interleukin-2 (IL-2) in the first-line treatment of patients with high-risk neuroblastoma and in two single-arm studies in the R/R setting. In the SIOPEN trial (HR-NBL1), the five-year event-free survival (EFS) rate in patients treated with dinutuximab beta was 57% vs. 42% of historical controls (p<0.01) and five-year overall survival (OS) rate was 64% vs. 50% (p0.0001).ii The safety of dinutuximab beta has been evaluated in 514 patients. The most common adverse reactions were pyrexia and pain that occurred despite analgesic treatment. Other frequent adverse reactions were hypersensitivity, vomiting, diarrhea, capillary leak syndrome, and hypotension.

About QARZIBA (dinutuximab beta)

QARZIBA is a monoclonal antibody that is specifically directed against the carbohydrate moiety of disialoganglioside 2 (GD2), which is overexpressed on neuroblastoma cells. Dinutuximab beta was approved by the European Commission in 2017 (See EMA Summary of Product Characteristics (SmPC)) and is indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with a history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilized by other suitable measures.

About EUSA Pharma

Founded in March 2015, EUSA Pharma is a world-class biopharmaceutical company focused on oncology and rare disease. The company has extensive commercial operations in the United States and Europe, alongside a direct presence in select other markets across the globe. EUSA Pharma is led by an experienced management team with a strong record of building successful pharmaceutical companies and is supported by significant funding raised from leading life science investor EW Healthcare Partners. For more information please visit http://www.eusapharma.com.

BeiGene Oncology

BeiGene is committed to advancing best and first-in-class clinical candidates internally or with like-minded partners to develop impactful and affordable medicines to patients across the globe. We have a growing R&D team of approximately 2,300 colleagues dedicated to advancing more than 90 clinical trials involving more than 13,000 patients and healthy volunteers. Our expansive portfolio is directed by a predominantly internalized clinical development team supporting trials in more than 40 countries. Hematology-oncology and solid tumor targeted therapies and immuno-oncology are key focus areas for the Company, with both mono- and combination therapies prioritized in our research and development. The Company currently markets three medicines discovered and developed in our labs: BTK inhibitor BRUKINSA in the United States, China, Canada, and additional international markets; and non-FC-gamma receptor binding anti-PD-1 antibody tislelizumab and PARP inhibitor pamiparib in China.

BeiGene also partners with innovative companies who share our goal of developing therapies to address global health needs. We commercialize a range of oncology medicines in China licensed from Amgen and Bristol Myers Squibb. We also plan to address greater areas of unmet need globally through our collaborations including with Amgen, Bio-Thera, EUSA Pharma, Mirati Therapeutics, Seagen, and Zymeworks. BeiGene has also entered into a collaboration with Novartis granting Novartis rights to develop, manufacture, and commercialize tislelizumab in North America, Europe, and Japan.

About BeiGene

BeiGene is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. With a broad portfolio of more than 40 clinical candidates, we are expediting development of our diverse pipeline of novel therapeutics through our own capabilities and collaborations. We are committed to radically improving access to medicines for two billion more people by 2030. BeiGene has a growing global team of approximately 7,000 colleagues across five continents. To learn more about BeiGene, please visit http://www.beigene.com and follow us on Twitter at @BeiGeneGlobal

BeiGene Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding the planned launch, potential benefits to patients, and opportunity of QARZIBA in China, and other information that is not historical information. Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeiGene's ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeiGene's ability to achieve commercial success for its marketed products and drug candidates, if approved; BeiGene's ability to obtain and maintain protection of intellectual property for its technology and drugs; BeiGene's reliance on third parties to conduct drug development, manufacturing and other services; BeiGenes limited operating history and BeiGene's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the section entitled Risk Factors in BeiGenes most recent quarterly report on Form 10-Q, as well as discussions of potential risks, uncertainties, and other important factors in BeiGene's subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeiGene undertakes no duty to update such information unless required by law.

QARZIBA is a registered trademark of EUSA Pharma (UK), Ltd.

GL-DNB-2100014. August 2021.

__________________

References

i European Medicines Agency, Qarziba (previously Dinutuximab beta EUSA and Dinutuximab beta APEIRON Biologics). Accessed: August 2021 via https://www.ema.europa.eu/en/medicines/human/EPAR/qarziba#authorisation-details-section.

ii Ladenstein, R et al. Cancers 2020, 12, 309; doi:10.3390/cancers12020309.

Read more:
BeiGene and EUSA Pharma Announce China NMPA Approval of QARZIBA (Dinutuximab Beta) for Patients With High-Risk Neuroblastoma - Business Wire

Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic – OncLive

When utilizing a validated antibody assay against the SARS-CoV-2 spike protein, investigators revealed a high seroconversion rate of 94% among 200 patients with cancer in New York City who had received a full dose of 1 of the FDA-authorized COVID-19 vaccines.

Patients with solid tumors experienced an impressive seroconversion rate of 98% compared with a rate of 85% in those with hematologic malignancies, 70% in those who had received highly immunosuppressive therapies like anti-CD20 agents, and 73% in those who had previously undergone stem cell transplantation. Notably, patients who received treatment with immune checkpoint inhibitors or hormonal therapies experienced seroconversion rates of 97% and 100%, respectively, following vaccination.

We saw very encouraging [data] showing that most patients with a cancer diagnosis have a really high chance of responding to vaccinationsas long as the vaccinations are done in an appropriate manner, [with] both doses administered, Balazs Halmos, MD, MS, study author, director of Thoracic Oncology, and director of Clinical Cancer Genomics at Montefiore Medical Center, told OncLive in an exclusive interview on the research. This was [true] even for [patients who were receiving] active treatment with chemotherapy, targeted therapy, or immunotherapy.

Halmos and colleagues launched this study to develop a better understanding with regard to the immunogenicity of vaccines in a group of patients with a cancer diagnosis in New York City by examining the rates of anti-spike immunoglobulin G (IgG) antibody positivity after receiving 1 of the 3 authorized COVID-19 vaccines.

A total of 213 patients were enrolled to the study through an informed-consent process. Twenty-nine additional patients with cancer who received the SARS-CoV-2 spike IgG testing were identified through retrospective chart review.

A total of 18 patients did not have this test conducted following consent, and thus, they were excluded from the analysis. Twenty additional patients were excluded because they had their test done before having received full vaccination in accordance with FDA guidance. Four additional patients were excluded for other reasons.

As such, 233 patients with cancer were noted to have received all required doses of their COVID-19 vaccine; all these patients were included in the safety analysis. A subset of 200 patients received the IgG test and were included in the immunogenicity analysis. Serological information from these patients were utilized in association studies between cancer subtypes and therapies.

Investigators also examined the link between the quantitative titer of SARS-CoV-2 spike IgG and cancer subtypes and therapies. If the 200 patients, 185 had available IgG titers that were at least 2 days following the last vaccine dose. A total of 15 patients were excluded from the vaccination cohort with titers; these patients had received the vaccine, but titers were checked less than 1 week from their last dose.

Among those included in the efficacy analysis (n = 200), the median age was 67 years (range, 27-90), 58% were female, and 42% were male. The study population was noted to be representative of the diverse population that resides in the Bronx, New York, with 32% of patients identifying as African American, 39% as Hispanic, 22% as Caucasian, 5% as Asian, and 3% as other ethnicities.

Additionally, 67% of patients had a solid tumor diagnosis and 33% had a hematologic malignancy. Among those with solid tumors, 26% had breast cancer, 14% had gastrointestinal cancer, 9% had genitourinary cancer, 5% had gynecologic cancer, 13% had thoracic or head and neck cancer, 1% had skin or musculoskeletal cancer, and 1% had carcinoma of an unknown primary. Among those with hematologic malignancies, 13% had lymphoid disease, 9% had myeloid disease, and 11% had plasma cell disease.

Seventy-five percent of patients had an active malignancy and 67% were receiving active treatment at the time that they received the COVID-19 vaccine. Fifty-six percent of patients were on active chemotherapy. Moreover, 19% of patients were on active chemotherapy within 48 hours of receiving at least 1 of their COVID-19 vaccine doses.

Fifty-four percent of patients completed vaccination with the Pfizer vaccine, 31% with the Moderna vaccine, and 10% with the Johnson & Johnson vaccine. A total of 3 patients had received a complete mRNA vaccination series but the information regarding the type of vaccine (Pfizer vs Moderna) are not yet available.

Additional findings from the study showed that significantly higher titer values were observed in solid tumors vs hematologic malignancies among a subgroup of 185 patients with available IgG titers longer than 7 days post vaccination, at a median of 7858 AU/mL vs a median of 2528 AU/mL, respectively (P = .013).

When comparing patients who were receiving active cancer treatment vs those who were not, no significant differences in seroconversion were reported, at 96% and 93%, respectively. However, investigators did report lower seropositivity rates in those who were on active cytotoxic chemotherapy versus other treatments, at 92% vs 99%, respectively (P = .04). Moreover, significantly lower seroconversion rates were also noted in those who received immunosuppressive therapies like stem cell transplant (73%; P = .0002), CD20 antibody therapy (70%; P = .0001), or CAR T-cell therapy (all seronegative; P = .0002).

Significantly lower titer levels were observed in patients who received CD20 antibody therapy vs the overall patient population, which underscored the susceptibility of patients receiving these treatments during the pandemic.

No statistically significant associations between age, ethnicity, time since immunosuppressive therapy, steroid use, or treatment within 48 hours of a vaccine dose, and seropositivity were reported.

Although all patients who were receiving CDK4/6 inhibitor treatment demonstrated positive anti-spike IgG test results, notably antibody titers were noted to be very low in this subset (n = 5), at a median of 1242 AU/mL vs a median of 6887 AU/mL in the overall cohort. Given the known involvement of the CDK4/6 pathway in immune activation, this might be biologically plausible and warrants further studies into the impact of CDK4/6 inhibitors on vaccine efficacy, the study authors noted.

A trend to lower titers were also reported among subsets of patients who received BCL-2 or BTK inhibitors.

Among a subset of 22 patients with cancer who had previously been infected with COVID-19, the seroconversion rate was 95%. Notably, antibody titers in those who had prior infection with the virus were found to be significantly higher than those who did not have a known prior infection, at a median of 46,737 AU/mL and a median of 5296 AU/mL, respectively (P < .001).

Our study, along with other emerging data, strongly highlights the continued need to vaccinate patients with a cancer diagnosis urgently and broadly, as vaccinations are likely to be highly effective, the study authors concluded. On the other hand, our study highlights at-risk cohorts of patients, in particular patients with hematologic malignancies following receipt of immunosuppressive therapies such as stem cell transplantation, anti-CD20 therapies, and CAR T-cell treatments. These cohorts of patients could potentially benefit from passive immunization with anti-COVID antibodies in the face of the ongoing pandemic.

See original here:
Study Calls for COVID-19 Vaccination in Patients With Cancer to Enable Optimal Treatment Delivery During Pandemic - OncLive

Animal Stem Cell Therapy Market Identify Key Drivers, Trends, Latest Innovations, Business Senario, Demand With Outlook by 2026 – The Market Writeuo -…

According to a new research report titled Animal Stem Cell Therapy Market Global Industry Perspective, Comprehensive Analysis And Forecast by 2021 2026

This has brought along several changes in This report also covers the impact of COVID-19 on the global market.

The report provides revenue forecasts for global, regional and country levels. It also provides comprehensive coverage on major industry drivers, restraints, and their impact on market growth during the forecast period. For the purpose of research, The Report has segmented global Animal Stem Cell Therapy market on the basis of types, technology and region

Get a Sample PDF copy of Animal Stem Cell Therapy Market @ https://www.reportsinsights.com/sample/493406

Key Competitors of the Global Animal Stem Cell Therapy Market are: MediVet Biologic, VETSTEM BIOPHARMA, J-ARM, Celavet, Magellan Stem Cells, U.S. Stem Cell, Cells Power Japan, ANIMAL CELL THERAPIES, Animal Care Stem, Cell Therapy Sciences, VetCell Therapeutics, Animacel, Aratana Therapeutics

The Global Animal Stem Cell Therapy Market Research Report is a comprehensive and informative study on the current state of the Global Animal Stem Cell Therapy Market industry with emphasis on the global industry. The report presents key statistics on the market status of the global Animal Stem Cell Therapy market manufacturers and is a valuable source of guidance and direction for companies and individuals interested in the industry.

To get this report at a profitable rate.: https://www.reportsinsights.com/discount/493406

Regional Animal Stem Cell Therapy Market (Regional Output, Demand & Forecast by Countries):- North America (United States, Canada, Mexico) South America ( Brazil, Argentina, Ecuador, Chile) Asia Pacific (China, Japan, India, Korea) Europe (Germany, UK, France, Italy) Middle East Africa (Egypt, Turkey, Saudi Arabia, Iran) And More.

The research report studies the past, present, and future performance of the global market. The report further analyzes the present competitive scenario, prevalent business models, and the likely advancements in offerings by significant players in the coming years.

Key Questions answered by the Report

Access full Report Description, TOC, Table of Figure, Chart, etc. @ https://www.reportsinsights.com/industry-forecast/animal-stem-cell-therapy-market-statistics-493406

About US:

Reports Insights is the leading research industry that offers contextual and data-centric research services to its customers across the globe. The firm assists its clients to strategize business policies and accomplish sustainable growth in their respective market domain. The industry provides consulting services, syndicated research reports, and customized research reports.

Contact US:

Email:[emailprotected]

Sales:[emailprotected]

Original post:
Animal Stem Cell Therapy Market Identify Key Drivers, Trends, Latest Innovations, Business Senario, Demand With Outlook by 2026 - The Market Writeuo -...

Treatment of AML in Older Patients Almost At ‘The Holy Grail’ – Curetoday.com

Recent drug approvals in the acute myeloid leukemia (AML) space have allowed older patients with the disease to continue receiving less intensive therapies than their younger counterparts, while also providing them with improved outcomes.

Were almost at the holy grail where (we) have lower intensity therapy thats well tolerated, but that the response rates are higher, said Dr. Tapan Kadia, an associate professor in the department of leukemia at The University of Texas MD Anderson Cancer Center in Houston, in an interview with CURE. Theyre not reaching (the 85% seen) with intensive chemotherapy, but (theyre) much better.

Kadia recently presented on the topic of treating older patients with AML during CUREs Educated Patient Leukemia Summit and highlighted how its vastly different than treating younger, and more fit patients.

He explained how the incidence of AML increases as a person gets older and that 60% of people who receive a diagnosis are aged older than 60 years.

Because more than half of the patient population with AML is aged older than 60 years, Kadia stressed that treatment approaches should be individualized for each patient. And, he said, factors such as their comorbidities, age, ability to tolerate chemotherapy and whether they could be candidate for a stem cell or bone marrow transplant in the future should play a role in selecting which treatment option they receive.

The major point to get across (is) to characterize a leukemia and to provide a therapy thats best for that patient long term, he said.

Although younger patients with the disease tend to receive more intensive chemotherapy regimens, it is tougher to administer those same regimens to older patients because it can wipe out their blood cell counts and it is difficult to deliver in a safe way, Kadia explained. In addition, older patients are more likely to have comorbidities such as heart disease, diabetes or COPD, which must also be managed in an intensive chemotherapy setting.

In years past, the lower intensity therapies were more tolerable, but they were not associated with great response rates. However, with the recent Food and Drug Administration approval of Venclexta (venetoclax), overall response rates increased to 65% and complete remission rates now are in the range of 35% to 40% when combined with drugs such as decitabine or azacitidine), Kadia explained. He said that these regimens are associated with very, very good outcomes with a median survival of 14.5 months, and the older patients tolerate it better.

Typically, patients who have AML and are in remission undergo a stem cell transplant or bone barrow transplant. However, for an older patient, a transplant is too risky. Regardless, Kadia noted that their remission should be maintained. Maintenance therapy is then used in this population to keep their disease in remission. Maintenance therapy usually consists of low-intensity, long-term treatment that can maintain the diseases response and help prevent the leukemia from returning.

What most people need to realize is that most subsets of AML are incurable, he said. That means (the disease) will typically try to come back if not treated aggressively and long term. And so this maintenance therapy allows people to maintain remission once they have achieved it.

We have really had a revolution in the treatment of AML, where previously we only had two or three drugs to treat AML and many people got intensive chemotherapy, Kadia concluded. We are fortunate now to live in an era where we have nine new drugs approved just in the last five years.

For more news on cancer updates, research and education, dont forget tosubscribe to CUREs newsletters here.

Read the rest here:
Treatment of AML in Older Patients Almost At 'The Holy Grail' - Curetoday.com

8 Tips for Coping With a Diagnosis of PPMS – Everyday Health

Primary-progressive multiple sclerosis (PPMS) is known for being an especially debilitating form of multiple sclerosis in which disability steadily worsens over time, sometimes quickly. This form of MS affects about 10 to 15 percent of people diagnosed with multiple sclerosis.

Typically, people with PPMS do not have distinct periods of relapse or remission, as is the case with more common form of MS, relapsing-remitting MS.

While there are approaches for controlling the symptoms of PPMS, treatments for the condition are limited: Only one medication, Ocrevus (ocrelizumab), has been approved by the U.S. Food and Drug Administration (FDA) for slowing the progression of PPMS.

RELATED: 10 Essential Facts About Primary-Progressive MS

Because PPMS is progressive and often disabling, receiving a diagnosis can be traumatic.

Beth Broun, a New York City native who now lives upstate, received her diagnosis 10 years ago. The 56-year-old first noticed something was wrong when her left leg began feeling weak, and she started tripping over her left foot.

My husband and I were walking on the Upper West Side [of Manhattan], and my left foot completely flopped, Broun says.

Her primary care physician sent her to a neurologist who was not an MS expert. He advised her to get physical therapy, but after six months nothing had changed.

It took her two years before she consulted another neurologist who ordered a brain scan and spotted the tell-tale signs of MS.

RELATED: Advances in Diagnosing Multiple Sclerosis

I freaked out, says Broun. She called her husband and told him the news and then did what she thought was the next most essential thing: I went to Bergdorf Goodman, and I bought a $3,500 handbag, because thats what you do when youre diagnosed.

After getting over the initial shock of the diagnosis, Broun started the gradual process of coming to terms her condition and then creating a plan to deal with the symptoms. Here are some tips that can help anyone who is newly diagnosed with PPMS.

As director of the MS Comprehensive Care Center at Stony Brook Neurosciences Institute, Patricia Coyle, MD,treats patients with PPMS and understands why a diagnosis is especially traumatic.

As you learn more about the disease, you realize that primary-progressive MS is a more significant form, where there is basically inevitable disability, says Dr. Coyle.

Coyle stresses, however that an education program is extremely important, because it can reduce fears. The more people know, the better they are able to deal with the illness and to find the information they need about therapies and disease progression that can provide them with the hope to go on and develop coping skills to live with the illness.

Coyle says that people need to know that they can clinically stabilize, sometimes for up to several years, and they can even see some improvement its in the minority, but that can occur.

Because the pace of worsening of PPMS doesnt tend to change over time, people who have it have some idea of what to expect from year to year.

Still, its important to have medical providers who can talk with you about what youre experiencing.

I think you want to have a relationship with your healthcare providers where you are free to ask any questions that you have, Coyle says.

A good starting point to find answers to commonly asked questions about PPMS is the National Multiple Sclerosis Society (NMSS). The website of the Multiple Sclerosis Association of America is another good place to find authoritative information about the various types of MS, including PPMS.

But, Broun cautions, dont automatically trust all of the advice or assertions about MS that you might read online, even when a person appears to write with great authority. Some of what she read along the way convinced her that she might go blind or lose her ability to speak. Having a medical provider who can help you sort out whats real and whats not can be a big help in these situations.

Along these lines, Coyle cautions about internet scams that promise miracle cures and prey on desperate patients.

If you read, We have stem cells that will improve your MS; you only need to pay $20,000, that's not legitimate, she says. There is no documented stem cell treatment for MS at this point in time.

Having PPMS doesnt mean you have to stop working. Its symptoms and progression are unique to each individual, so the illness doesnt have to mean an end to career.

In an article for Roche Pharmaceuticals, professor Jrme de Seze, PhD, the department head of the Neurology and Clinical Investigation Centre at the University of Strasbourg in France, wrote that most PPMS patients he deals with are keen to keep working.

Coyle emphasizes that a diagnosis doesnt have to be a career-ender. While this is a more severe form of MS, people can still continue to function for prolonged periods of time, she says.

Because some of the symptoms such as fatigue and cognitive impairment may limit ones ability to work, an individual may seek to work part-time.

The NMSS provides a legal guide for people with MS that addresses many workplace-related questions, such as "Am I obligated to tell my employer about my MS diagnosis?" and "Can I be let go from my job because of my MS?"

Work situations are always going to vary, but Coyle notes that some employers may be sympathetic.

An informed employer could actually be potentially very helpful with regard to accommodations, she says.

RELATED: 6 Top Tech Recommendations for Primary-Progressive MS

Broun says that the No. 1 thing to do is to put together a trusted health support team. This can include a neurologist, primary care provider, physical therapist, and mental health professional.

In Brouns case, it took some trial and error to find an MS care provider who felt right for her. But after consulting with different specialists, Broun found that Saud Sadiq, MD, a neurologist at the Tisch MS Research Center in New York City, provides guidance and treatment options that she believes in.

RELATED: Shared Decision-Making for MS Treatment

A mental health professional can be a key member of your health support team.

Its not uncommon for patients early in diagnosis to go through an adjustment period of anxiety and some depression when they hear they have MS, says Laura Safar, MD, an assistant professor of psychiatry at Brigham and Womens Hospital in Boston and a psychiatrist who treats psychiatric disorders among people with multiple sclerosis. Patients may have fears about their prognosis, and questions about what their progression will be like.

Individuals cope in different ways, Dr. Safar says. Some of them can be very proactive and want to learn about everything they can do to improve their health. Others can be overwhelmed, and avoid dealing with the diagnosis and treatment.

Safar says that it can be helpful for clinicians to observe how different patients cope with their illness to understand what type of support or interventions they need in addition to educating them about the diagnosis and next steps for treatment.

Doctors and patients alike should be aware that PPMS can affect a persons cognition, or their ability to think, remember, and perform other mental tasks.

Depending on a persons needs, appropriate interventions may include a neuropsychological evaluation to assess cognition, or a referral to a psychotherapist or psychiatrist to focus on emotional and coping issues. Mental health therapy may involve both talking through problems and taking antidepressants.

Rehabilitation therapies including physical, occupational, and cognitive rehabilitation can be tools to sustain and improve a patient's cognitive and functional abilities.

From a psychological perspective, rehabilitationstrategies, when combined with disease-modifyingtreatment, can assist in providing a sense of mastery over their illness, she says.

Ultimately, Safar says that her goal is to help individuals figure out how do I make this illness a part of my life, but not let it define the whole of who I am and what my life is about.

Safar notes that ideally, friends and family members should be part of the support network a person with MS relies on.

I want to make sure that people are not isolated and not alone, she says. So I find out if they have friends or family they can talk to about their diagnosis.

Safar recognizes that for some it can be difficult to even share they are ill. They are concerned that a partner may not be supportive or may turn away. Or they fear that they will cause too much worry among family members. They want to protect their loved ones and their relationships, she says.

Because she firmly believes that patients should not take this on alone, she advises some to take gradual steps toward disclosing information about the diagnosis and see how people close to them react.

RELATED: How MS Contributes to Isolation and What You Can Do to Stay Connected

In addition to seeking emotional support from friends and family, people with PPMS may also want to connect with one or more online groups.

Through participating in several MS groups on Facebook, Broun developed a deep friendship with another person with PPMS who lives in the Netherlands, and they each push the other to be proactive about their illness.

We say were going to fight each other; were going to outrun each other, she jokes. Hes a force.

For those looking for online support and connection, Broun suggests exploring Moodify, the PPMS Facebook page, as well as the International Progressive MS Alliance.

While looking after your mental state is vital to living with PPMS, so is doing your best to maintain good physical health. Broun gets around nowadays with a walker. She says its brutal to see herself in the mirror that way, but without exercise, she might not even be walking.

Exercise is the No. 1 thing to me, says Broun.

When she was first diagnosed, Broun began working with a physical therapist to maintain mobility and function. She started doing leg presses and walking on an uphill treadmill for 10 minutes to build strength in her glutes, hip flexors, and hamstrings.

Currently, she meets with a personal trainer two times a week to work on her muscle strength and balance, which she describes as incredibly weak. Because Broun has foot drop (difficulty lifting the front part of her foot), she does special exercises to keep her foot up.

My favorite exercise, which may not be specific forMS but makes me feel dynamite, is riding a spin bike, says Broun. You would never know I have a MS when Im riding it, but as soon as I get off I can barely walk. I love the confidence and ego boost I get from it.

On her visits with Dr. Sadiq, she also works with a new therapist on a special robotic machine, which helps someone like me use muscles I havent used in years.

To get started with exercise on your own, the Multiple Sclerosis Trustprovides a series of strength, stretching, balance, and breathing exercises for people with MS to explore and use to build their own routine for physical activity.

Following a healthy diet is also important for maintaining strength and stamina. For Broun, this means sticking to a Mediterranean-type diet, primarily consisting of organic proteins and vegetables.

At the end of the day, says Broun, I can control my exercising, and I can control what I can eat to feel good otherwise, MS is an animal, and its going to take over my body.

Coyle recommends exploring the many MS apps on the market for tracking symptoms and other purposes.

Apps have a number of different functions they can help track activities, track what youre doing in terms of exercise, and enable you to easily look up information related to MS, she says.

The Multiple Sclerosis Clinical Care App, for example, contains current information on the diagnosis, classification, and management of multiple sclerosis (MS), concisely presented for use at the point of care.

Several appsare available that allow you to track symptoms, notes TeamScope. My MS Manager, created and supported by the Multiple Sclerosis Association of America, is one such example.

The National MS Society recommends Happy the App, a 24/7 phone-based emotional support service via mobile app that connects individuals experiencing everyday stresses, struggles, anxiety, or loneliness with exceptionally compassionate listeners.

Read the original post:
8 Tips for Coping With a Diagnosis of PPMS - Everyday Health